Genetic Signatures Finalizes Restructuring and Secures Danish Hospital Contract to Boost European Expansion

Organisational Restructuring Achieves $5 Million Annual Cost Savings

Genetic Signatures successfully concluded its organisational restructuring, initially announced in March 2026, resulting in 30 redundancies across five divisions and creation of three new project management roles. One-off redundancy payments totaling $0.8 million, including accrued leave, were fully settled in Q4 FY2026 and reflected in cash flow statements.

This restructuring is projected to deliver $5 million in annual cost savings starting FY2027, complementing operational efficiencies identified during the company's strategic review. These savings aim to create a leaner operational base, supporting Genetic Signatures’ multi-horizon growth strategy by fostering a sustainable cost structure while expanding into new geographic markets and advancing product development, thereby enhancing financial performance and capital efficiency as revenue growth stabilises.

Danish Healthcare Partnership Validates EasyScreen™ Platform Across Europe

In April 2026, Genetic Signatures secured a 10-year supply agreement with Denmark’s Hvidovre Hospital, a leading public healthcare provider. The contract includes supply of instruments, reagents, and consumables for the gastrointestinal EasyScreen™ molecular diagnostic product, with options to extend for two additional 12-month periods. Installation and validation of equipment at Hvidovre Hospital were completed in June 2026, marking a key milestone in commercial deployment.

The hospital placed its first commercial order on 10 July 2026, confirming the clinical utility and market readiness of Genetic Signatures’ pan-enteric diagnostic solution in a major European healthcare setting. Combined with performance data from EasyScreen™ deployments in the UK and other markets, this agreement underscores tangible benefits for hospital labs, clinicians, and patients, signaling momentum for broader adoption across European healthcare systems and supporting sales expansion into Scandinavian and continental European markets.

Strategic Review Establishes Three-Horizon Growth Plan for FY2027

In June 2026, Genetic Signatures completed a thorough strategic review covering all business functions, including HR, operations, and key markets in Australia, the US, and Europe. The review outlined a growth framework with three horizons: stabilising existing operations to ensure steady revenue; optimising resources through restructuring and outsourcing; and scaling via new products and geographic expansion, especially across EMEA and APAC regions.

The plan includes pausing and resetting US operations, leveraging momentum in EMEA through partnerships like Hvidovre, and pursuing emerging APAC opportunities. The company will continue exploring strategic partnerships for new diagnostic product development and market access alongside organic growth.

Shift to Contract Research Partnerships Lowers Fixed Development Costs

Genetic Signatures is progressively outsourcing parts of its product development to specialist contract research organisations while retaining core intellectual property and technical expertise internally. This hybrid approach, initiated in prior quarters, aims to access flexible, high-quality development capabilities while reducing fixed labour and facility expenses.

During the quarter, internal resources expanded the respiratory pathogen detection portfolio, while development of a new enteric pathogen detection product was outsourced to meet specific European customer needs and open APAC market opportunities. This model accelerates time-to-market for new diagnostics while preserving assay design, regulatory, and clinical validation competencies, aligning with the three-horizon growth strategy without proportional increases in headcount or infrastructure.

Pricing Strategy Adjusted to Enhance Long-Term Profitability

Following a comprehensive review, Genetic Signatures adjusted its product and instrument pricing to improve profitability and secure enduring customer relationships. Pricing changes maintain competitiveness in healthcare tenders while ensuring financial returns. Near-term gross margins may decline as customers transition to new pricing and competitive pressures persist in some markets.

The company expects improved unit economics as revenue volumes grow and fixed costs remain stable, supported by the $5 million annual cost savings. This aligns with strategic goals to secure long-term contracts like the Hvidovre Hospital deal, providing revenue stability. The Optimus Prime instrument project is paused indefinitely as the company evaluates alternative solutions and potential partnerships to meet market needs without full in-house development costs.

Financial Performance Reflects Benefits of Cost Management

Genetic Signatures reported Q4 FY2026 sales of $3.1 million, contributing to FY2026 total revenue of $14.8 million. Q4 revenue was impacted by competitive pressures, Australian pricing changes, and lower testing volumes partly due to a delayed influenza season, although international operations performed strongly. Customer receipts were $3.0 million for the quarter.

Net operating cash outflow was $3.4 million in Q4 FY2026, including $0.8 million in one-off redundancy payments. Excluding these, the underlying cash outflow was $2.6 million, improving from $3.5 million in the prior quarter, indicating early effects of cost reductions. No significant investing cash outflows occurred during the quarter; full-year equipment investments of $1.0 million were made in the first three quarters. Payments to Directors and Officers, including the CEO, totalled $0.3 million and are included in staff costs in the Appendix 4C cash flow statement.

Strong Cash Position Supports Growth Without Immediate Capital Raise

As of 30 June 2026, Genetic Signatures held $22.1 million in cash and equivalents, including $18.1 million in cash and $4.0 million in term deposits. Although term deposits are classified as "other financial assets" in the Annual Report, they are included as cash equivalents in the Appendix 4C to reflect availability for operations and strategic initiatives. This cash reserve provides substantial flexibility to execute the three-horizon growth plan without needing an immediate capital raise.

The $22.1 million balance covers approximately 1.5 years of operating cash outflows at the Q4 FY2026 rate before full realisation of cost savings. It enables funding for outsourced product development, scaling of the EasyScreen™ platform in EMEA and APAC, and pursuit of strategic partnerships without depleting working capital. The cash buffer also mitigates near-term revenue fluctuations from seasonal testing, competitive dynamics, and timing of new orders like Hvidovre Hospital.

Board Leadership Changes Align with Strategic Execution

Board changes announced in the March 2026 quarterly report took effect on 1 May 2026. Ms Anne Lockwood stepped down as Interim Managing Director and became a Non-Executive Director and Chair of the Audit Committee. Dr Neil Gunn resigned as Non-Executive Director on the same date. These changes concluded transitional governance arrangements and established the board structure to oversee the three-horizon growth strategy through FY2027 and beyond.

Ms Lockwood’s continued role as Non-Executive Director and Audit Committee Chair ensures governance continuity during strategic execution, while her departure from the Interim Managing Director role allows focus on operational and market expansion under the permanent management team announced earlier.

FY2027 Outlook Focuses on Disciplined Growth and Strategic Partnerships

Entering FY2027, Genetic Signatures is positioned with a clear strategic framework to drive growth across three horizons. The outlook is supported by long-term contracts like the 10-year Hvidovre Hospital agreement, offering revenue visibility and stability. The company remains committed to disciplined cost management to enhance operational efficiency and capital deployment, leveraging the $5 million annual savings to improve profitability while investing in product development and market expansion.

Growth initiatives include developing new diagnostics for current and new markets, pursuing commercial partnerships to accelerate market access and product timelines, and advancing the EasyScreen™ molecular diagnostic platform as the portfolio cornerstone. Expansion of respiratory pathogen detection and new enteric pathogen products will continue. Management expresses confidence in the strategic direction established through the comprehensive review and operational progress demonstrated by the Hvidovre Hospital installation and initial commercial order in July 2026.